Mr. Duvall was appointed Tocagen’s Chief Executive Officer in November 2016 and also joined the company’s board of directors. He holds over 30 years of oncology drug development and commercialization experience, including building successful oncology teams in both large pharma organizations and biotech companies. Most recently, Mr. Duvall was executive Vice President, Chief Commercial Officer at Ariad Pharmaceuticals where he led the company’s growth and transformation into a fully integrated, global biotechnology company. Previously, he was Senior Vice President and General Manager for the oncology franchise at Merck and & Co., Inc. Prior to this role he was Senior Vice President, Global Marketing and International Operations at Abraxis Bioscience (acquired by Celgene), and Senior Vice President, Commercial Operations and Strategy/Development at MGI Pharma (acquired by Eisai Co., Ltd.). He held positions of increasing responsibility for nearly 20 years at Sanofi and its predecessor companies. Mr. Duvall holds a master’s degree in chemistry from Johns Hopkins University, master’s degree in business from The University of Kansas and bachelor’s degree in chemistry from Muhlenberg College.